Kornimate/medical-research-clean huggingface dataset:
evaluation of surface acoustics ultrasound device for the treatment of patients with percutaneous nephrostomy catheters

Conditions: Urinary Tract Infection

Summary: catheter associated urinary tract infection is one of the most common types of catheter acquired infections and adds greatly to patient morbidity, mortality and medical cost. urinary catheters may readily acquire biofilms when inserted. the longer the catheter remains in place, the greater the tendency of these organisms to develop biofilms and result in urinary tract infections, which are difficult to treathe uroshield system is intended to prevent bacterial biofilm formation by means of the active nanoshield technology it has developed. a number of scientific concepts and principles shown in prior studies have shown some promising results in the treatment of biofilm based sequele using ultrasound energy. the nanoshield technological basis of the uroshield system has taken these concepts to a level where acoustical waves in the ultrasound range can be created by low cost disposable actuators which actually create a physical coating on all of the surfaces of the catheter thereby interfering with the attachment of bacteria which is the initial step in biofilm formation.

the uroshield™ system is comprised of 2 main components:· the disposable uroshield z-patch - a disposable small lightweight patch that is attached to the pcn catheter, while its opposite side is attached directly to the patient's skin at the site of catheter entry. the patch has twofold function: 1. it receives energy and a signal from the uroshield driver allowing it to generate the ultrasonic waves; 2. it acts as a fixation device for the pcn catheter.· the uroshield driver - an external driver unit that is attached to the uroshield patch and contains batteries to power the system and electronics that control the patch unit

Eligibility criteria:
inclusion criteria: * patients requiring percoutaneous nephrostome * first insertion exclusion criteria: * blood coagulation disorders * trauma

Keywords: surface acoustic ultrasound biofilm formation percoutaneous nephrostomy tube patients requiring per coetaneous drainage due to urinary tract obstruction to evaluate the efficacy of surface acoustic wave in reducing pain and improving drainage
effects of compression stockings in asthma symptoms at night

Conditions: Asthma

Summary: nocturnal worsening of asthma is common. it is characterized by overnight exacerbation of asthma symptoms such as shortness of breath, chest tightness, coughing, and wheezing, increased need of asthma medications and airway hyperresponsiveness, and decline in lung function (1). nocturnal asthma has been attributed in part to circadian variations in lung function and airway inflammation. however, other factors including sleep, supine posture and lung volume may also contribute to nocturnal asthma. current treatments often improve nighttime asthma symptoms. nevertheless, nocturnal asthma is still common. up to 2/3rd of asthma patients report nocturnal asthma symptoms, and many asthma related events occur at night, indicating poor asthma control. results from an ongoing study suggest that in asthma while subjects were supine, fluid shifted out of the legs and accumulated in the thorax (rostral fluid shift) contributing to lower airway narrowing in asthma. a previou study has shown that wearing compression stockings during the day reduces fluid retention in the legs, reduces nocturnal rostral fluid shift out of the legs, and improves sleep apnea (2, 3). the aims of the proposed study is investigate whether off-the-shelf, below the knee compression stockings will attenuate nocturnal fluid shift and lower airway narrowing in asthma.


Eligibility criteria:
inclusion criteria: non-smokers or former smokers (\<10 pack/year) exclusion criteria: uncontrolled hypertension

Keywords: asthma fluid shift compression stockings intrathoracic airway narrowing
dose of norepinephrine and the concentration of l-lactate in the rectum and stomach in patients with septic shock.

Conditions: Septic Shock

Summary: norepinephrine is a drug used to increase blood pressure in patients with life-threatening infection. however, norepinephrine may limit the bloodflow to the gut, thereby causing relative lack of oxygen to the cells. this leads to increased formation of lactic acid. this study examines whether increasing the dose of norepinephrine leads to higher concentrations of lactic acid in the rectum and stomach in patients with life-threatening infection.


Eligibility criteria:
inclusion criteria: * septic shock * ne-dose \> 0.1 microg/kg/min * ci \> 3.0 l/min/m2 exclusion criteria: * age \< 18, unable to obtain informed consent from relatives * untreated hypertension * pregnancy * pathology in the rectum or stomach * limitation of therapy
detection and pathogenesis of novel protein f

Conditions: Cardiac Disease; Multiple Myeloma

Summary: from december 6, 2019 to march 23, 2020, the research group of qingkun fan found a novel protein(temporarily named protein f) in heparin anticoagulant plasma of three patients with heart disease. one patient was diagnosed with multiple myeloma.however, protein f cannot be detected by serum protein electrophoresis. preliminary studies have shown that this novel protein f have an obvious absorption peak at about 600nm. placed at 2-8 degrees for 7 days, protein f will be isolated from heparin plasma. to the naked eye, protein f appear to be transparent jelly between the red blood cells and the plasma. the specific protein f, how it is produced, how it causes disease are still unknown. this study will explore how to detect protein f and how it is produced.

protein f screening was performed on anticoagulant blood plasma with heparin lithium or blood serum by in-house turbidimetric method in automatic biochemical analyzer. all patients were followed-up for 3 years by telephones, routine appointment out-patient clinic or returning visit.

Eligibility criteria:
inclusion criteria: * testing total protein and albumin * testing routine blood test exclusion criteria: * high triglycerides (tg\>5.00 mmol/l) * hyperbilirubinemia (tbil\>170 mmol/l) * fat emulsion used in past 3 days * patients with hemolytic disease * pregnant and lactating women

Keywords: diagnosis protein cardiac disease multiple myeloma globulin
conversations in health literacy using ai technology for osteoarthritis patients

Conditions: Osteoarthritis; Osteoarthritis of the Hip or Knee

Summary: the goal of this clinical trial is to assess the use of a generative artificial intelligence large language model chatbot in improving decision making factors in patients with hip and knee osteoarthritis. the main questions it aims to answer are: does the use of an artificial intelligence chatbot have an effect on decisional conflict and anxiety related to decision making? are changes in decisional conflict correlated with changes in patient reported outcomes? are changes in decisional conflict correlated with health literacy? participants will interact with an artificial intelligence chatbot prior to their clinic visit with an orthopaedic surgeon, using a structured prompt.


Eligibility criteria:
inclusion criteria: * adult * ability to read and write in english * all races and ethnicities * clinical symptoms of hip and/or knee osteoarthritis exclusion criteria: * inability to read and write in english

Keywords: artificial intelligence health literacy decisional conflict
study of carboplatin/paclitaxel with or without investigational drug (cs-7017) in subjects with metastatic non-small cell lung cancer

Conditions: Metastatic Non-small Cell Lung Cancer

Summary: the study has a safety and a phase 2 portion. in the safety portion of the study, subjects with metastatic non-small cell lung cancer will be treated with study drug (cs-7017) in combination with carboplatin and paclitaxel to evaluate safety. in the phase 2 portion of the study, subjects will receive study drug (cs-7017) or placebo in combination with carboplatin and paclitaxel to evaluate effectiveness and safety. the study will find out if adding cs-7017 to carboplatin and paclitaxel will be safe and improve progression free survival in subjects with metastatic non-small cell lung cancer.


Eligibility criteria:
inclusion criteria: * histologically or cytologically confirmed metastatic (stage iv) nsclc with no significant pleural effusion or pleural involvement from the tumor * age greater than or equal to 18 years * adequate organ and bone marrow function exclusion criteria: * any prior systemic therapy for nsclc * major surgical procedure or other investigational agents within 4 weeks before study enrollment * need for concomitant use of other thiazolidinediones during the study * history of any of the following conditions within 6 months prior to initiating study treatment: diabetes mellitus requiring treatment with insulin or sulfonylureas or thiazolidinediones (tzds) agents; myocardia infarction with significant impairment of cardia function; malabsorption syndrome, chronic diarrhea, inflammatory bowel disease or partial bowel obstruction; * clinically active brain metastases, uncontrolled seizure disorder; spinal cord compression or carcinomatous meningitis
the fasting ii study

Conditions: Diabetes; Metabolic Diseases

Summary: this study will determine whether an intensive fasting protocol alters hemoglobin a1c measurements or other markers of metabolic and cardiovascular risk by performing a 5-week clinical trial of fasting among 12 pre-diabetic individuals or diabetics whose disease is controlled by diet. participants will undergo a 5-week intervention of once-per-week 24-hour water-only fasting, including at baseline and at the end of the week for each week of the study (a total of 6 24-hour fasts).


Eligibility criteria:
inclusion criteria: 1. male or non-pregnant female, ≥30 and \<70 years of age. 2. ability to understand and sign a written informed consent form, which must be obtained prior to initiation of any study procedures. 3. prior evidence of pre-diabetic state, with one of the following: 1. pre-diabetic with a measured hemoglobin a1c (hba1c) ≥6.0% or fasting glucose \>100 mg/dl without a clinical diabetes diagnosis 2. clinically-diagnosed type ii diabetic with hba1c ≥6.0% or fasting glucose ≥110 mg/dl and whose disease is controlled by diet alone. 4. evidence of metabolic syndrome by having at least 3 of the following 5 criteria: 1. fasting glucose level \>100 mg/dl. 2. blood pressure ≥135 mmhg systolic or ≥85 mmhg diastolic, or use of an antihypertensive medication. 3. high-density lipoprotein cholesterol \<40 mg/dl in males or \<50 mg/dl in females. 4. triglycerides ≥150 mg/dl or use of a cholesterol-lowering medication. 5. waist circumference \>40 inches (102 cm) for males or \>35 inches (88 cm) for females (or body mass index \>25 kg/m2). exclusion criteria: 1. pregnant and/or lactating women and women of child bearing potential who are not using acceptable means of contraception. women of childbearing potential must be using adequate measures of contraception (as determined by the principal investigator) to avoid pregnancy and should be highly unlikely to conceive during the study period. women of childbearing potential must have a negative pregnancy test at screen. 2. diabetics taking any of the following anti-diabetic medications: insulin, metformin, thiazolidinediones, sulfonylureas, alpha-glucosidase inhibitors, meglitinides, or incretins. 3. prior experience with fasting more than once per month (for 20 hours or more), on average during the last year. 4. very low body mass index (bmi) (\ 40 kg/m2). 5. individuals who are nutritionally compromised, as assessed by the principal investigator. 6. any immunodeficiency or prior solid organ transplantation or renal disease. 7. participation in any other clinical trials involving investigational or marketed products within 30 days prior to entry in the study. 8. other conditions that in the opinion of the principal investigator may increase risk to the subject and/or compromise the quality of the clinical trial.

Keywords: diabetes fasting pre-diabetes hemoglobin a1c
gw572016 for treatment of refractory metastatic breast cancer

Conditions: Neoplasms, Breast

Summary: this study was designed to determine the efficacy of an oral dual kinase inhibitor for the treatment of metastatic breast cancer tumors that are known to overexpress erbb2 in a refractory patient population.


Eligibility criteria:
inclusion criteria: * signed informed consent. * histologically confirmed stage iiib or iv breast cancer. * refractory breast cancer defined as progression in the metastatic setting after prior therapy with anthracyclines, taxanes and capecitibine. * subjects with documented erbb2 tumor overexpression must have received at least 6 cycles of trastuzumab. * documented disease progression of the most recent treatment is required. * archived tumor tissue available for testing. * measurable lesions according to response evaluation criteria in solid tumors (recist). * at least 3 weeks since prior cancer therapies except for trastuzumab which must be discontinued at least 2 weeks prior to the beginning of study drug. * bisphosphonate therapy initiated prior to study entry is allowed, however, initiation of bisphosphonates following study entry is not allowed. * able to swallow and retain oral medication. * cardiac ejection fraction within the institutional normal range as measured by echocardiogram or muga (multiple gated acquisition) scan. * adequate kidney and liver function. * adequate bone marrow function. exclusion criteria: * pregnant or lactating. * copies of nadir scans and/or photographs of the tumor prior to disease progression as well as scans documenting disease progression are not available for review. * malabsorption syndrome, ulcerative colitis, disease significantly affecting gastrointestinal function or resection of the stomach or small bowel. * history of other malignancy. * serious medical or psychiatric disorder that would interfere with the patient''s safety or informed consent. * active or uncontrolled infection. * known history of uncontrolled or symptomatic angina, arrhythmias or congestive heart failure. * known history of or clinical evidence of leptomeningeal carcinomatosis. * active infection. * concurrent cancer therapy or investigational therapy. * use of oral or iv steroids. * unresolved or unstable serious toxicity from prior therapy. * prior treatment with an erbb1 and/or erbb2 inhibitor other than trastuzumab.

Keywords: lapatinib metastatic breast cancer herceptin refractory
the pronto study, a global phase 2b study of neod001 in previously treated subjects with light chain (al) amyloidosis

Conditions: AL Amyloidosis

Summary: this is a global, multicenter, phase 2b, randomized, double-blind, placebo-controlled, two-arm, parallel-group efficacy and safety study of neod001 as a single agent administered intravenously in adults with al amyloidosis who had a hematologic response to previous treatment for their amyloidosis (e.g., chemotherapy, autologous stem cell transplant \[asct\]) and have persistent cardiac dysfunction.


Eligibility criteria:
inclusion criteria: 1. age ≥18 years 2. confirmed diagnosis of systemic al amyloidosis 3. ≥1 prior systemic plasma cell dyscrasia therapy with at least a partial hematologic response 4. cardiac involvement 5. nt-probnp ≥650 exclusion criteria: 1. non-al amyloidosis 2. meets the international myeloma working group (imwg) definition of multiple myeloma 3. nt-probnp \>5000 4. received plasma cell directed chemotherapy within 6 months 5. received autologous stem cell transplant (asct) within 12 months

Keywords: amyloidosis ntprobnp neod001 prothena pronto amyloid plasma cell dyscrasia immunotherapy
clinical cross reactions between anacardiaceae

Conditions: Suspected Allergy to Anacardiaceae

Summary: the prevalence of food allergies has increased in recent decades, ranging from 1 to 3% of the general population. according to international literature and french national surveys, nuts today represent a group of allergens often associated with severe allergic reactions. they are responsible for 18 to 40% of deaths from food-related anaphylaxis. among all nuts, the prevalence of anacardiac allergies (mainly cashew and pistachio) continues to increase and has become a growing public health problem. today, global production is estimated at 4.9 million tonnes of cashews and 1.1 million tonnes of pistachios. the resulting increased exposure may explain the increased prevalence of allergic reactions reported to these fruits. in addition, anaphylactic reactions to anacardiaceae are reported to be even more severe than those occurring in subjects allergic to peanuts. cashews and pistachios are known to exhibit immunological cross-reactions with one another. in fact, they have a strong sequential homology between their storage allergens ana o 1 / pis v 3 (7s vicilin, 78% homology); ana o 2 / pis v 2 (legume 11s, 80% homology) and ana o 3 / pis v 1 (albumin 2s, 70% homology). for this reason, some authors talk about the cashew / pistachio syndrome and associate the two allergenic sources by considering them as one, in clinical practice. the diagnosis of allergy to nuts, and therefore to anacardiaceae, is based on a compatible clinical history, the presence of specific ige (demonstrated by positivity to realistic skin tests and serum ige assay), and positivity on the oral food challenge test. in clinical practice, taking into account the cashew / pistachio syndrome, when the allergy work-up for cashew is negative, allergists tend to advise to reintroduce pistachio at home, considering the two allergens as sufficiently homologous to authorize such a practice. in this context, the investigators decided to check whether this practice, which is based mainly on in vitro homologies, is risk-free, based on the clinical experience of our center.


Eligibility criteria:
inclusion criteria: * patient evaluated at the allergy unit of the university hospital of montpellier (france) * suspicion of food allergy to anacardiaceae * allergy work-up for cashew and pistachio including at least skin tests, and possible specific ige and food challenge exclusion criteria: - patients included in other trials that don't allow them to be included in the present one

Keywords: food allergy skin tests food challenge cashew pistachio
mobichina - a prospective multicenter cohort study

Conditions: Unstable Fracture; Hip Fracture

Summary: the study will assess the difference in functionality between early vs. standard mobilization after hip fracture in the chinese population.

the primary objective of this prospective observational cohort study is to assess the difference in functionality between group i and ii (see mobilization regimens for the two groups above) at 6 weeks using the modified barthel index in the chinese population. the allocation of patients to the two groups will be performed on a clinic level: 50% of patients will be recruited by study sites in group i (early mobilization). the other 50% of patients will be recruited by study sites in group ii. the sites are carefully selected after evaluating their standard procedures of mobilizing elderly patients after hip fractures. this process is documented using formal site selection questionnaires. the modified barthel index is estimated at 75 points for group ii and at 85 points for group i. patients aged 65 years and older with unstable intertrochanteric fractures (ao 31 a2 or a3) treated with an intramedullary nail will be included in this study. the study visits will be defined as preoperative, surgery, discharge, 6 (± 2) weeks and 12 (± 2) weeks follow-up (fu) visits. furthermore, there will be a telephone contact 12 months (± 1 month) postsurgery.

Eligibility criteria:
inclusion criteria: * age 65 and older * diagnosis of an unstable intertrochanteric fractures (ao 31- a2 or a3) treated with an intramedullary nail * ability to walk independently or with a walking aid prior to injury * informed consent obtained, i.e.: ability of the patient to understand the content of the patient information / informed consent form and signed and dated institutional review board (irb) / ethics committee (ec)-approved written informed consent exclusion criteria: * severe dementia * recent history of substance abuse (ie, recreational drugs, alcohol) that would preclude reliable assessment * prisoner * participation in any other medical device or medicinal product study within the previous month that could influence the results of the present study

Keywords: geriatrics [mesh] hip fractures [mesh] china [mesh] early ambulation [mesh] immobilization [mesh]
structured shared decision making for patients undergoing savr or tavr

Conditions: Aortic Valve Stenosis; Symptomatic Aortic Stenosis

Summary: transcatheter aortic valve replacement (tavr) is a well-established alternative to surgical aortic valve replacement (savr) for the treatment of patients with severe aortic stenosis regardless of surgical risk. while tavr and savr share some of the benefits and risks, they importantly differ with regards to invasiveness, time to recovery, hemodynamics, as well as options for re-intervention and possibly valve durability. an early benefit of tavr may be offset by late risks. therefore, current guidelines of the european society of cardiology recommend an integration of patient values and preferences for the selection of the treatment modality. the objective of the together trial is to investigate the efficacy of a structured shared decision making approach (sdm) to improve patient-centered outcomes for the choice between savr and tavr. together is an investigator-initiated, randomized, open-label, single-center clinical trial. a total of 140 patients referred for treatment of symptomatic severe aortic stenosis and deemed to undergo tavr or savr according to heart team decision will be randomized in a 1:1 ratio to structured sdm or usual care.


Eligibility criteria:
inclusion criteria: 1. age ≥ 70 years 2. symptomatic severe aortic stenosis defined by an aortic valve area ≤1.0 cm2 or an aortic valve area indexed to body surface area \<0.6cm2/m2 3. both savr and transfemoral tavr as reasonable treatment options based on heart team decision exclusion criteria: 1. life expectancy \<1 year irrespective of valvular heart disease 2. inability to provide informed consent 3. participation in another clinical trial with an active intervention

Keywords: symptomatic aortic stenosis aortic valve stenosis savr (surgical aortic valve replacement) shared decision-making tavr (transcatheter aortic valve replacement) tavi (transcatheter aortic valve implantation) decision support techniques